A protein aggregation platform that distinguishes oligomers from amyloid fibrils
The Analyst · 2023
DOI: 10.1039/d3an00487b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Analyst, 2023. Verfasst von Amy Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. zhef…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Using a combination of split and intact β-lactamase constructs, we designed a protein aggregation screening platform that can distinguish changes in amyloid oligomers from overall protein aggregation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. zhefeng@ucla.edu.
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- National Institute on Aging
Zitieren
APA
Zhang, A., Portugal Barron, D., Chen, E. W., & Guo, Z. (2023). A protein aggregation platform that distinguishes oligomers from amyloid fibrils. The Analyst. https://doi.org/10.1039/d3an00487b
Vancouver
Zhang A, Portugal Barron D, Chen EW, Guo Z. A protein aggregation platform that distinguishes oligomers from amyloid fibrils. The Analyst. 2023. doi:10.1039/d3an00487b
BibTeX
@article{Zhang2023,
author = {Zhang, Amy and Portugal Barron, Diana and Chen, Erica W and Guo, Zhefeng},
title = {A protein aggregation platform that distinguishes oligomers from amyloid fibrils},
journal = {The Analyst},
year = {2023},
doi = {10.1039/d3an00487b}
}
EUVIMED